vs
Side-by-side financial comparison of Dole plc (DOLE) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.3B, roughly 1.0× Dole plc). Zoetis runs the higher net margin — 25.3% vs 0.2%, a 25.0% gap on every dollar of revenue. On growth, Dole plc posted the faster year-over-year revenue change (10.5% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $66.5M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 3.2%).
Dole plc is an Irish-American agricultural multinational corporation headquartered in Dublin, Ireland. The company is among the world's largest producers of fruit and vegetables, operating with 38,500 full-time and seasonal employees who supply some 300 products in 75 countries. Dole reported 2021 revenues of $6.5 billion.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
DOLE vs ZTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.4B |
| Net Profit | $5.1M | $603.0M |
| Gross Margin | 6.8% | 70.2% |
| Operating Margin | 1.1% | 31.9% |
| Net Margin | 0.2% | 25.3% |
| Revenue YoY | 10.5% | 3.0% |
| Net Profit YoY | -64.6% | 3.8% |
| EPS (diluted) | $0.05 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.4B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.4B | $2.5B | ||
| Q1 25 | $2.1B | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $2.1B | $2.4B | ||
| Q2 24 | $2.1B | $2.4B | ||
| Q1 24 | $2.1B | $2.2B |
| Q4 25 | — | $603.0M | ||
| Q3 25 | $5.1M | $721.0M | ||
| Q2 25 | $10.0M | $718.0M | ||
| Q1 25 | $38.9M | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | $14.4M | $682.0M | ||
| Q2 24 | $80.1M | $624.0M | ||
| Q1 24 | $70.1M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | 6.8% | 71.5% | ||
| Q2 25 | 9.0% | 73.6% | ||
| Q1 25 | 8.7% | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | 8.0% | 70.6% | ||
| Q2 24 | 9.4% | 71.7% | ||
| Q1 24 | 9.2% | 70.6% |
| Q4 25 | — | 31.9% | ||
| Q3 25 | 1.1% | 37.0% | ||
| Q2 25 | 4.3% | 36.7% | ||
| Q1 25 | 3.2% | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | 2.3% | 36.6% | ||
| Q2 24 | 4.0% | 33.0% | ||
| Q1 24 | 5.3% | 34.1% |
| Q4 25 | — | 25.3% | ||
| Q3 25 | 0.2% | 30.0% | ||
| Q2 25 | 0.4% | 29.2% | ||
| Q1 25 | 1.9% | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | 0.7% | 28.6% | ||
| Q2 24 | 3.8% | 26.4% | ||
| Q1 24 | 3.3% | 27.4% |
| Q4 25 | — | $1.37 | ||
| Q3 25 | $0.05 | $1.63 | ||
| Q2 25 | $0.10 | $1.61 | ||
| Q1 25 | $0.41 | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | $0.15 | $1.50 | ||
| Q2 24 | $0.84 | $1.37 | ||
| Q1 24 | $0.74 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $321.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $3.3B |
| Total Assets | $4.5B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $321.0M | $2.1B | ||
| Q2 25 | $323.1M | $1.4B | ||
| Q1 25 | $261.0M | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $266.4M | $1.7B | ||
| Q2 24 | $225.8M | $1.6B | ||
| Q1 24 | $245.5M | $2.0B |
| Q4 25 | — | $3.3B | ||
| Q3 25 | $1.4B | $5.4B | ||
| Q2 25 | $1.4B | $5.0B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | $1.4B | $5.2B | ||
| Q2 24 | $1.4B | $5.0B | ||
| Q1 24 | $1.3B | $5.1B |
| Q4 25 | — | $15.5B | ||
| Q3 25 | $4.5B | $15.2B | ||
| Q2 25 | $4.7B | $14.5B | ||
| Q1 25 | $4.5B | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | $4.5B | $14.4B | ||
| Q2 24 | $4.4B | $14.2B | ||
| Q1 24 | $4.5B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.4M | $893.0M |
| Free Cash FlowOCF − Capex | $66.5M | $732.0M |
| FCF MarginFCF / Revenue | 2.9% | 30.7% |
| Capex IntensityCapex / Revenue | 0.9% | 6.7% |
| Cash ConversionOCF / Net Profit | 17.12× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $13.7M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $893.0M | ||
| Q3 25 | $87.4M | $938.0M | ||
| Q2 25 | $18.3M | $486.0M | ||
| Q1 25 | $-78.8M | $587.0M | ||
| Q4 24 | — | $905.0M | ||
| Q3 24 | $101.0M | $951.0M | ||
| Q2 24 | $40.2M | $502.0M | ||
| Q1 24 | $-35.0M | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | $66.5M | $805.0M | ||
| Q2 25 | $-1.0M | $308.0M | ||
| Q1 25 | $-131.6M | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | $79.9M | $784.0M | ||
| Q2 24 | $22.8M | $370.0M | ||
| Q1 24 | $-53.2M | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | 2.9% | 33.5% | ||
| Q2 25 | -0.0% | 12.5% | ||
| Q1 25 | -6.3% | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | 3.9% | 32.8% | ||
| Q2 24 | 1.1% | 15.7% | ||
| Q1 24 | -2.5% | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | 0.9% | 5.5% | ||
| Q2 25 | 0.8% | 7.2% | ||
| Q1 25 | 2.5% | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | 1.0% | 7.0% | ||
| Q2 24 | 0.8% | 5.6% | ||
| Q1 24 | 0.9% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 17.12× | 1.30× | ||
| Q2 25 | 1.84× | 0.68× | ||
| Q1 25 | -2.02× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 7.01× | 1.39× | ||
| Q2 24 | 0.50× | 0.80× | ||
| Q1 24 | -0.50× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOLE
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
